中文 English

Singlera Genomics signs strategic partnership with Shanghai Genechem Co., Ltd.

Joint partnership for future success
January 10, 2017 - Shanghai, China
Singlera Genomics, Inc. signed a strategic partnership with Shanghai Genechem Co., Ltd. (GeneChem) to consolidate clinical and scientific services for cancer precision medicine. By combining the core competencies of each company, the collaboration between the two complementary companies will contribute to common innovation and development in precision medicine. The agreement focuses on next generation sequencing (NGS) for clinical and research services and custom projects, and takes advantage of the services and customer resources of both companies. Thus, the agreement allows for cooperative promotion of technologies for cancer precision medicine to improve healthcare.
In attendance at the signing ceremony were Jiangli Zhang, co-founder and CEO of Singlera Genomics, Rui Liu, co-founder and CTO of Singlera Genomics, Jia Zhu, Director of Marketing for Singlera Genomics, Yueqiong Cao, Chairman and President of Genechem, Di He, GM of Quality Control for GeneChem, Yangsheng Jin, representing the Board of Directors of GeneChem, Mingwei Xu, VP of Medicine for GeneChem, and additional managers from both companies.
GeneChem’s Chairman and President Yueqiong Cao commented how NGS has become a central technology platform for cancer precision medicine, and is an well-established clinical detection technology. NGS-based assays, including early cancer screening technology, developed by Singlera Genomics are considered leading edge for diagnostics and disease monitoring. This agreement will effectively increase GeneChem’s footprint in precision medicine and expand the coverage of GeneChem’s services. Co-founder and CEO of Singlera Genomics, Jiangli Zhang, remarked that the realization of cancer precision medicine involves research studies, with subsequent translational studies leading to clinical utility, considered the “driving force” in the development of cancer precision medicine. GeneChem is a mature company with a well-known brand and widely recognized scientific services, especially in clinical translation. The partnership with GeneChem will connect Singlera Genomics with diverse sectors of the medical industry, with the goal of fully implementing Singlera Genomics’ model of NGS services.
About Shanghai Genechem Co., Ltd.
Shanghai Genechem Co., Ltd. (GeneChem) was founded based on the pioneering functional genetic research in China and has built a complete translational medicine research platform. GeneChem is the largest provider of functional genetic research services in China, including the largest RNAi lentivirus library in China containing hundreds of genes with key functions for specific cancers. By cooperating with over 7,000 physicians from more than 10 areas in cancer research, GeneChem has created a broad platform for gene therapy research and development.
About Singlera Genomics, Inc.
Singlera Genomics, Inc. is a privately held company dedicated to the development of NGS-based diagnostic tests, covering early, accurate and informative diagnoses of cancer, prenatal diagnosis, pre-implantation genetic screening and customized scientific research services, including cancer targeted therapies. Singlera Genomics has two sites: headquarters and clinical operations in Shanghai, China and Research and Development Laboratory in San Diego, CA. For more information, please visit www.singlera.com.

返 回